Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 CAD | +5.85% | +2.84% | -35.22% |
Mar. 26 | Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 26 | Transcript : Aptose Biosciences Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Sales 2024 * | - | Sales 2025 * | 2.08M 1.54M | Capitalization | 32.22M 23.8M |
---|---|---|---|---|---|
Net income 2024 * | -84M -62.05M | Net income 2025 * | -39M -28.81M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 15.5 x |
P/E ratio 2024 * |
-0.24
x | P/E ratio 2025 * |
-0.37
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.74% |
Latest transcript on Aptose Biosciences Inc.
1 day | +5.85% | ||
1 week | +2.84% | ||
Current month | -9.58% | ||
1 month | -12.50% | ||
3 months | -33.44% | ||
6 months | -42.29% | ||
Current year | -35.22% |
Managers | Title | Age | Since |
---|---|---|---|
William Rice
CEO | Chief Executive Officer | 65 | 13-10-27 |
C. Payne
DFI | Director of Finance/CFO | 61 | 22-06-26 |
Roger Davies
COO | Chief Operating Officer | - | 21-10-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Burger
BRD | Director/Board Member | 80 | 07-09-18 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 22-09-12 |
Mark Vincent
BRD | Director/Board Member | 71 | 07-09-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.17 | +5.85% | 3 500 |
24-03-27 | 2.05 | -3.76% | 7,400 |
24-03-26 | 2.13 | +3.90% | 1,501 |
24-03-25 | 2.05 | -1.91% | 2,340 |
24-03-22 | 2.09 | -0.95% | 9,133 |
Delayed Quote Toronto S.E., March 28, 2024 at 11:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.22% | 23.71M | |
+8.83% | 45.97B | |
+52.22% | 43.93B | |
+7.85% | 42.34B | |
-8.78% | 28.27B | |
+17.97% | 27.18B | |
-20.55% | 19.44B | |
+14.47% | 13.83B | |
+31.83% | 12.4B | |
+9.34% | 11.45B |